The EM Community Found ANOTHER Amazing Stock!

TL;DR

Dita, a dialysis company, has a market cap of $7 billion, high debt, but strong free cash flow. Sales have remained flat, but the company has been buying back shares. Berkshire Hathaway owns a significant stake in the company.

Transcript

this next stock is a request from our community our very active Community thousands of members talk about our investments this is the stock they want to hear about we did it on a live stream I said this looks interesting the stock is Dita they do dialysis inhome dialysis or in home or is it at um I'm not sure if they do in home they definitely have... Read More

Key Insights

• 💐 Dita has a market cap of $7 billion and high debt, but its strong free cash flow and low valuation make it an attractive investment opportunity.
• 🥶 The company's sales have remained flat, but its significant share buybacks have increased access to free cash flow for investors.
• 😘 Dita's competitors, such as Foren Medical Care, have similar valuations but lower debt levels and higher dividend payouts.
• 💐 Potential risks include government policies and the industry's stagnant growth, but Dita's low valuation and strong cash flow provide significant potential returns.

Questions & Answers

Q: What is Dita's market capitalization and debt level?

Dita has a market cap of $7 billion and an enterprise value of $21 billion, indicating significant debt.

Q: How does Dita's free cash flow compare to its net income?

Dita's free cash flow is significantly higher than its net income, indicating strong cash generation potential for shareholders.

Q: How many facilities does Dita have, and how many patients does it treat annually?

Dita has 3,000 facilities worldwide and treats 240,000 patients globally per year.

Q: What is the main source of Dita's sales revenue?

Dita receives about two-thirds of its sales from US government Medicare reimbursement rates.

Q: Why has Dita's profit been fluctuating in recent years?

Dita's profit has been inconsistent, possibly due to factors such as government cutbacks and the industry's stagnant growth.

Q: Who are Dita's major competitors, and how do they compare?

Foren Medical Care is Dita's biggest competitor, with similar price-to-free cash flow ratios but lower debt and higher dividends.

Q: What are the positives and negatives of investing in Dita?

Positives include a low valuation, strong free cash flow, and significant share buybacks. Negatives include high debt levels and potential risks from government policies.

Q: What are the analyst estimates for Dita's earnings and revenue growth?

Analysts expect earnings per share to reach $10 in the next four years, with revenue growing from $12 billion to $13.45 billion.

Summary & Key Takeaways

• Dita is a dialysis company with facilities worldwide and treats 240,000 patients annually.

• The company has a market cap of $7 billion, high debt, but strong free cash flow of $1.36 billion.

• Sales have remained flat, but the company has been buying back shares, resulting in increased access to free cash flow for investors.